Here are the 424B prospectus supplements from PAVmed Inc. (PAVM) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PAVM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PAVM filings page.
PAVmed Inc. (PAVM) is establishing a new at-the-market equity program, allowing it to sell up to $9.4 million of common stock from time to time through or to A.G.P./Alliance Global Partners as sales agent or principal. A.G.P. will receive a 3.0% commission on the gross sales price of shares sold.
The company intends to use any net proceeds for working capital and general corporate purposes. As an illustration, if 1,846,758 shares are sold at $5.09 per share (the September 3, 2026 Nasdaq closing price), net tangible book value per share would rise to $3.54 while new investors would face about $1.55 of immediate dilution per share.
PAVmed highlights a history of operating losses, substantial doubt about its ability to continue as a going concern, challenges raising capital, significant outstanding convertible and equity-linked securities, and the possibility of additional future financings that could further dilute existing shareholders and pressure the share price.
PAVmed Inc. registered 9,230,786 shares of common stock for resale by selling stockholders, consisting of 4,615,393 shares issued upon conversion of Series D preferred and 4,615,393 shares issuable upon exercise of related warrants. The company is not selling shares here and will not receive proceeds from resales; it may receive up to $30,000,000 to the extent the Warrants are exercised. The registration covers resale by the listed selling stockholders and permits the shares to be sold on exchanges, OTC or by negotiated transactions, at the selling holders' discretion.